Financial News

Recent Quotes
My Watchlist
Indicators
Motherlode Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aimmune Therap (NQ: AIMT )

34.49 USD UNCHANGED
Last Price Updated: 7:11 PM EDT, Oct 12, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Stories about Aimmune Therap

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Aimmune Therapeutics (AIMT) Q2 2020 Earnings Call Transcript
AIMT earnings call for the period ending June 30, 2020. 
Tags AIMT Market News
From Motley Fool
The Daily Biotech Pulse: Bristol-Myers, Bluebird Bio Resubmit Multiple Myeloma Drug BLA, FSD To Close Medicinal Cannabis Business, Hologic's Blowout Quarter
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ... 
Tags SBPH NKTX HOLX
From Benzinga
Got $2,000? Investing in These 3 Small-Cap Stocks Can Make You Rich
These under-the-radar names pack some huge growth potential. 
Tags CRLB/F FOUR Market News
From Motley Fool
2 Top Cancer Treatment Stocks To Watch In July
These hidden gems have the potential to deliver significant returns to their shareholders over the long run. 
Tags ALXN GILD CTMX
From Motley Fool
Analysts Anticipate PBSM To Hit $29
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Benzinga's Top Upgrades, Downgrades For July 13, 2020
Upgrades ForDarden Restaurants Inc(NYSE: DRI), JP Morgan upgraded the stock from Neutral to Overweight. Darden ... 
Tags ZYXI MSGE Consumer Discretionary
From Benzinga
Why DBV Technologies Is Plunging Today
The company provided a grim business update. 
Tags Market News DBVT AIMT
From Motley Fool
First Week of August 21st Options Trading For Aimmune Therapeutics (AIMT)
Investors in Aimmune Therapeutics Inc (AIMT) saw new options begin trading this week, for the August 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT... 
Tags Stocks
From Market News Video
Down 40% in 6 Months, Is Aimmune Therapeutics a Buy?
Armed with the recent approval of Palforzia, the first FDA-approved treatment for peanut allergy, could Aimmune Therapeutics turn things around? 
Tags DBVT Market News AIMT
From Motley Fool
Sum Up The Parts: IEIH Could Be Worth $34
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Aimmune says peanut allergy drug shows benefit after 2 years
Aimmune Therapeutics Inc said on Monday 80% of patients being treated with its drug Palforzia were successfully desensitized to peanut proteins after two years of daily dosing, sending its shares up... 
Tags companyNews
From Reuters: Company News
Why Are So Many Traders Betting Against the First Therapy for Peanut Allergies?
Short-sellers are convinced a company marketing the first approved biologic for treating peanut allergies in children and teenagers will fail. Here's why. 
Tags Market News AIMT NSRGY
From Motley Fool
Aimmune Therapeutics Inc (AIMT) Q1 2020 Earnings Call Transcript
AIMT earnings call for the period ending March 31, 2020. 
Tags AIMT Market News
From Motley Fool
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares ... 
Tags DARE PFE Benzinga
From Benzinga
First Week of December 18th Options Trading For Aimmune Therapeutics (AIMT)
Investors in Aimmune Therapeutics Inc (AIMT) saw new options begin trading this week, for the December 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay,... 
Tags Stocks
From Market News Video
Is Aimmune Therapeutics a Buy?
A recent drug approval, a competitor's setback, and a discounted stock price make Aimmune an intriguing investment. 
Tags Market News DBVT NSRGY
From Motley Fool
A Tale of 2 Biotechs With Competing Peanut Allergy Treatments
DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist. 
Tags AIMT Market News DBVT
From Motley Fool
Should You Buy These 4 Biotech Stocks With Recent Drug Approvals?
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now. 
Tags Market News AIMT ESPR
From Motley Fool
Downtrend Call Working As Aimmune Therapeu Stock Falls 46.8% (AIMT)
SmarTrend identified a Downtrend for Aimmune Therapeu (NASDAQ:AIMT) on February 6th, 2020 at $29.72. In approximately 2 months, Aimmune Therapeu has returned 46.77% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Aimmune Therapeu Shares Down 51.5% Since SmarTrend's Sell Call (AIMT)
SmarTrend identified a Downtrend for Aimmune Therapeu (NASDAQ:AIMT) on February 6th, 2020 at $29.72. In approximately 2 months, Aimmune Therapeu has returned 51.47% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Aimmune Therapeu Shares Down 54.6% Since SmarTrend's Sell Call (AIMT)
SmarTrend identified a Downtrend for Aimmune Therapeu (NASDAQ:AIMT) on February 6th, 2020 at $29.72. In approximately 2 months, Aimmune Therapeu has returned 54.56% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
Bargain Hunters Take Note: Insider Cluster-Buying At AIMT
A particularly strong insider buying signal is what we call a "cluster-buy" where three or more different insiders make open market purchases within a short period of one another. At Aimmune... 
Tags Stocks
From Market News Video
10 Biggest Price Target Changes For Monday
Citigroup cut the price target on The Middleby Corporation (NASDAQ: MIDD) from $115 to $54. Middleby closed at $47.07 on ... 
Tags NFLX HON GS
From Benzinga
Friday 3/20 Insider Buying Report: AIMT, DX
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. 
Tags Stocks
From Market News Video
UPDATE 2-FDA urges virtual patient visits as coronavirus disrupts clinical trials
The U.S. Food and Drug Administration on Wednesday recommended switching to virtual patient visits instead of in-person monitoring for clinical studies, as signs emerge that the rapid spread of the... 
Tags companyNews
From Reuters: Company News
UPDATE 1-Coronavirus begins disrupting clinical trials as companies try containing spread
U.S.-based Iveric bio Inc on Wednesday became the latest company to delay a clinical trial due to the coronavirus outbreak, as drug developers begin taking preventive measures to contain the... 
Tags companyNews
From Reuters: Company News
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ... 
Tags BBIO HOTH AXDX
From Benzinga
10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades
The COVID-19-induced sell-off has taken a toll on stocks across sectors. An analyst at Cantor Fitzgerald presented his take on how ... 
Tags Benzinga INO Charles Duncan
From Benzinga
Aimmune Therapeu Has Returned 62.6% Since SmarTrend Recommendation (AIMT)
SmarTrend identified a Downtrend for Aimmune Therapeu (NASDAQ:AIMT) on February 6th, 2020 at $29.72. In approximately 1 month, Aimmune Therapeu has returned 62.63% as of today's recent price of... 
From Comtex SmarTrend® News Briefs
18 Healthcare Stocks Moving In Tuesday's Pre-Market Session
Gainers • Moleculin Biotech, Inc. (NASDAQ:MBRX) stock rose 83.70% to $0.73 during Tuesday's pre-market session. • ... 
Tags TTOO BNTX Market News
From Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback